29.22

2.63% -0.83

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $29.22, with a volume of 137.28K. It is down -2.63% in the last 24 hours and down -8.16% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$30.05

Open:

$29.67

24h Volume:

137.28K

Relative Volume:

0.15

Market Cap:

$1.67B

Revenue:

$199.89M

Net Income/Loss:

$52.48M

P/E Ratio:

34.38

EPS:

0.85

Net Cash Flow:

$61.15M

1W Performance:

+1.95%

1M Performance:

-8.16%

6M Performance:

+105.05%

1Y Performance:

+176.04%

1-Day Range:

$28.75

$30.29

1-Week Range:

$27.01

$30.96

52-Week Range:

$5.35

$38.69

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1119)

Industry

Biotechnology (625)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

128

Twitter

@stoketx

Next Earnings Date

2025-03-18

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	29.25	1.72B	199.89M	52.48M	61.15M	0.85
VRTX Vertex Pharmaceuticals Inc	463.83	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	749.34	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	811.57	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	360.88	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.19	37.49B	4.98B	69.59M	525.67M	0.5197

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Resumed	Chardan Capital Markets	Buy
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Jan 21, 2026